Showing results (11-20 of 462) with videos related to
Sort By:
Pageof 47
Archives of Gynecology and Obstetrics|April 30, 2020
Diagnostic impact of ascites cytology in 941 patients: malignancy rates and time of detection in ovarian cancer relative to other tumor typesJens Krugmann, Corinna Lang Schwarz, Balint Melcher, et al.Archives of Gynecology and Obstetrics|June 1, 2020
Correction to: Diagnostic impact of ascites cytology in 941 patients: malignancy rates and time of detection in ovarian cancer relative to other tumor typesJens Krugmann, Corinna Lang Schwarz, Balint Melcher, et al.Human Pathology|May 23, 2018
Budding and tumor-infiltrating lymphocytes - combination of both parameters predicts survival in colorectal cancer and leads to new prognostic subgroupsCorinna Lang-Schwarz, Balint Melcher, Franziska Haumaier, et al.Archives of Gynecology and Obstetrics|November 12, 2018
Malignant ascites occurs most often in patients with high-grade serous papillary ovarian cancer at initial diagnosis: a retrospective analysis of 191 women treated at Bayreuth Hospital, 2006-2015Jens Krugmann, Corinna Lang Schwarz, Balint Melcher, et al.International Journal of Colorectal Disease|June 25, 2021
Programmed death ligand 1 (PD-L1) in colon cancer and its interaction with budding and tumor-infiltrating lymphocytes (TILs) as tumor-host antagonistsCorinna Lang-Schwarz, Balint Melcher, Arndt Hartmann, et al.Human Pathology|May 6, 2019
Budding, tumor-infiltrating lymphocytes, gland formation: scoring leads to new prognostic groups in World Health Organization low-grade colorectal cancer with impact on survivalCorinna Lang-Schwarz, Balint Melcher, Franziska Haumaier, et al.Microorganisms|January 20, 2021
Helicobacter Infection and Gastric AdenomaSimone Bertz, Miriam Angeloni, Jan Drgac, et al.International Journal of Colorectal Disease|March 21, 2021
Adjuvant chemotherapy in stage II and III colon cancer: the role of the "budding and TILs-(tumor-infiltrating lymphocytes) combination" as tumor-host antagonistsCorinna Lang-Schwarz, Balint Melcher, Theresa Dregelies, et al.Expert Review of Molecular Diagnostics|March 28, 2008
Implications of EGFR PharmDx kit for cetuximab eligibilityChristian Ensinger, William SterlacciCancers|February 13, 2026
An Algorithmic Approach for Quantitative Determination of Microsatellite Status in NGS-Based Cancer DiagnosticsJosefin Männlein, William SterlacciPageof 47